◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › A › ACRS

Aclaris Therapeutics Inc (ACRS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Aclaris Therapeutics Inc (ACRS) operates in the BIOTECHNOLOGY industry and is headquartered in Wayne, United States with about 69 employees. Its market capitalization is roughly $818 million. In the fiscal year ended 2025-12-31, ACRS reported $8M in revenue and ($65M) in net income.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.

Interactive charts & full statements → Open the ACRS valuation workbench →

ACRS Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Total Revenue$8M$8M$19M$31M$30M$7M$6M$4M$10M$2M$0M$0M$0M—
Gross Profit$8M$6M$16M$13M$18M$2M$1M$0M$3M$0M$0M$0M$0M—
Gross Margin %100.0%73.3%85.1%42.1%59.8%30.3%20.8%4.1%32.1%28.3%————
Operating Income (EBIT)($86M)($76M)($142M)($97M)($90M)($90M)($51M)($111M)($135M)($72M)($49M)($21M)($9M)($5M)
Operating Margin %-1075.0%-975.9%-758.2%-311.6%-302.0%-1327.1%-785.4%-2627.3%-1341.9%-4303.2%————
Net Income($77M)($65M)($132M)($88M)($87M)($91M)($51M)($161M)($133M)($69M)($48M)($21M)($9M)($5M)
Net Margin %-962.5%-829.6%-705.5%-283.2%-292.1%-1344.0%-789.2%-3817.2%-1315.4%-4071.5%————
EBITDA($75M)($64M)($52M)($115M)($84M)($64M)($50M)($90M)($134M)($72M)($48M)($21M)($9M)($5M)
Earnings Per Share (EPS)$-0.58$-0.53$-1.71$-1.27$-1.33$-1.60$-1.20$-3.90$-4.03$-2.44$-2.25$-1.10$-0.80$-3.13
Shares Outstanding (M)143M123M77M70M65M57M43M41M33M28M21M19M—2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACRS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$2M$2M$1M$3M$2M$1M$9M$4M
Gross Profit$1M$2M$2M$3M$0M$1M$0M$2M
Gross Margin %85.8%80.2%162.0%83.7%-4.1%65.2%-1.0%44.6%
Operating Income (EBIT)($24M)($22M)($23M)($17M)($18M)($18M)($100M)($10M)
Operating Margin %-1487.9%-1111.8%-1755.5%-519.8%-1035.9%-1242.9%-1082.1%-240.9%
Net Income($22M)($20M)($20M)($15M)($15M)($15M)($97M)($8M)
Net Margin %-1320.1%-993.2%-1528.6%-443.0%-868.3%-1036.8%-1048.2%-174.6%
EBITDA($21M)($20M)($20M)($14M)($17M)($18M)($14M)($9M)
Earnings Per Share (EPS)$-0.15$-0.15$-0.16$-0.12$-0.13$-0.12$-1.01$-0.11
Shares Outstanding (M)143M129M123M123M123M122M95M71M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACRS Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Cash from Operations (CFO)($62M)($47M)($20M)($78M)($68M)($52M)($39M)($96M)($101M)($55M)($35M)($20M)($8M)($5M)
Capital Expenditures (CapEx)$0M$0M$0M$1M$1M$0M$0M$2M$1M$1M$0M$1M$0M$0M
Free Cash Flow (FCF)($62M)($47M)($20M)($80M)($68M)($52M)($39M)($98M)($102M)($56M)($35M)($21M)($8M)($5M)
FCF Margin %-775.0%-603.4%-107.9%-254.8%-229.1%-775.6%-603.0%-2319.8%-1012.5%-3321.3%————
Dividends Paid—————$3M$8M——$0M$0M$0M——

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACRS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($20M)($18M)($13M)($11M)($10M)($13M)($9M)$22M
Capital Expenditures (CapEx)$0M$0M$0M$0M$0M$1M$36M$0M
Free Cash Flow (FCF)($20M)($18M)($13M)($11M)($10M)($14M)($45M)$22M
FCF Margin %-1221.9%-909.9%-1015.8%-332.1%-563.5%-957.6%-485.8%506.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ACRS Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Total Assets$180M$160M$220M$197M$255M$251M$71M$98M$276M$244M$176M$94M$17M$14M
Cash & Cash Equivalents$19M$20M$25M$40M$45M$27M$22M$36M$57M$209M$30M$10M$11M$10M
Total Liabilities$55M$57M$65M$40M$57M$54M$33M$28M$60M$18M$7M$2M$38M$23M
Total Debt (Short + Long-Term)$0M$1M$1M$0M$1M$1M$11M$1M$30M$0M$0M$0M$0M$0M
Total Shareholders' Equity$125M$103M$156M$157M$198M$197M$38M$70M$215M$225M$169M$93M($21M)($9M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACRS viewer.

Other Companies in BIOTECHNOLOGY

← ACROAll “A” companiesACRT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.